Olema Pharmaceuticals, Inc. cash flow to debt ratio of -12.30K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Olema Pharmaceuticals, Inc.'s free cash flow has decreased 40.38% from $-104.51M last year to $-146.72M, signaling decreasing performance

Olema Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Olema Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Olema Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Olema Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Olema Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Olema Pharmaceuticals, Inc.'s short-term assets of $515.45M exceed its short-term liabilities of $51.80M

Olema Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Olema Pharmaceuticals, Inc.'s return on equity of -45.95%, is lower than 15.00%, indicating bad performance

Olema Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Olema Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Olema Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Olema Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Olema Pharmaceuticals, Inc.'s yearly earnings has decreased 25.47% since last year from $-129.47M to $-162.45M, signaling decreasing performance

Olema Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -41.66% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Olema Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Olema Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Olema Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Olema Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Olema Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Olema Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Olema Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Olema Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Olema Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Olema Pharmaceuticals, Inc. has a price-to-book ratio of 2.54x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Olema Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue